Epinephrine Injection Recalled for Lack of Sterility Assurance
SterRx is recalling epinephrine in 0.9% sodium chloride injection (5 mg per 250 mL) nationwide due to lack of assurance of sterility. Affected lots are identified by codes S21255/BXA, S21264/BXH, and S21328/BZO.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable pharmaceutical (epinephrine) with a sterility defect. Non-sterile injectables present serious risk of infection and sepsis. Although the source text does not report specific hospitalizations or illnesses, the hazard—compromised sterility of a critical emergency medication—meets the severity threshold for Class II recalls involving risk of serious adverse health consequences.
Plain-English summary
SterRx, LLC is recalling EPINEPHIrine in 0.9% Sodium Chloride Injection, 5 mg per 250 mL (20 mcg per mL), NDC 70324-052-01, distributed nationwide in the United States. The recall encompasses 7548 bags affected by a lack of assurance of sterility.
The affected product was manufactured under lot codes S21255/BXA (22-Jan-22), S21264/BXH (29-Jan-22), and S21328/BZO (10-Mar-22). This is a Class II recall issued by the FDA.
Patients should consult their healthcare provider immediately if they have received this product. Hospitals and healthcare facilities should stop use of affected lots and return or destroy remaining inventory according to proper pharmaceutical disposal procedures.
The recalled product
- Product
- EPINEPHIrine in 0.9% Sodium Chloride Injection, 5 mg per 250 mL (20 mcg per mL), Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903, NDC 70324-052-01.
- Manufacturer
- SterRx, LLC
- Category
- Drug — Injectable / Epinephrine
- Hazard
- lack-of-sterility
- contamination-risk
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- S21255/BXA 22-Jan-22 S21264/BXH 29-Jan-22 S21328/BZO 10-Mar-22
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27